Adicet Bio, Inc. (ACET)
Adicet Bio, Inc.
131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 143
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Chen Schor BA, CPA, M.B.A. | CEO, President & Director | 899.58k | N/D | 1972 |
| Dr. Aya Jakobovits Ph.D. | Founder & Independent Director | 40k | N/D | 1956 |
| Dr. Blake Aftab Ph.D. | Senior VP & Chief Scientific Officer | 675.04k | N/D | 1981 |
| Dr. Francesco Galimi M.D., Ph.D. | Chief Medical Officer & Senior VP | 680.37k | N/D | 1968 |
| Mr. Brian Nicholas Harvey | Chief Financial Officer | 596.79k | N/D | 1961 |
| Dr. Donald Healey Ph.D. | Chief Technology Officer | N/D | N/D | 1962 |
| Ms. Amy Locke | Chief Human Resource Officer | N/D | N/D | N/D |
| Dr. Nancy L. Boman M.D., Ph.D. | Senior VP & Chief Regulatory Officer | N/D | N/D | N/D |
Descripción
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Adicet Bio, Inc. a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 6; Junta: 9; Derechos del accionista: 8; Compensación: 9.
